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This tool is designed to support primary care providers in managing urinary incontinence (UI) in women ≥ 18 years. UI is the involuntary loss of urine and it is an underdiagnosed disorder. 1 The treatment of UI involves a step-wise approach of non-pharmacological, pharmacological and in some cases surgical interventions. Providers should work with patients to create a treatment plan that considers patients' preferences, as well as the practicality, availability and affordability of treatment options. 12 • Experience constipation 8 • Feel pain or a burning feeling when they urinate 12 • Have an occupation that requires regular lifting 7  Identify if patient is taking medication that can effect urogenital system and urine retention, such as: 5 • Medications with anticholinergic side effects such as antihistamines, antidepressants, and antipsychotics • Calcium-channel blockers • Alpha-adrenergic agonists
Managing Urinary Incontinence in Women

SECTION A: Screening
Screening for urinary incontinence in women is important because many women live with this condition for years without bringing it to the attention of their primary care provider. The screening and diagnostic measures below will help to identify if your patient has: stress urinary incontinence (SUI), overactive bladder (OAB) or mixed urinary incontinence (MUI). Identifying your patient's type of UI will help direct their treatment plan.
Opportunities to screen for UI
Patients who are:
• Over 65 years of age • Postmenopausal • Presenting with urinary concerns • Diagnosed with conditions associated with an increased risk of UI (e.g. diabetes, obesity and neurologic disease) Scheduled for a:
• periodic health examination • pap smear • postpartum visit
Medical history
Assessing the medical history of your patient helps identify any predisposing risk factors 5 that can help clarify patient's urinary symptoms severity and identify potential underlying causes that may be treatable or require further evaluation. 2 Notes:
Referral indicators
If patient has or had one or more of the following conditions, consider conducting a work-up/or refer patient to an appropriate specialist  Assess the pelvic floor muscles
Ask the patient to contract the pelvic floor muscles around the examining fingers. 13 Consider that:
• normal pelvic floor muscles can voluntarily contract and relax 13 • overactive pelvic floor muscles do not relax 12 • underactive pelvic floor muscles cannot voluntarily contract 13 • non-functioning pelvic floor muscles present when no pelvic floor muscle action is palpable 13  Is pelvic organ prolapse suspected?
If yes, proceed to Section B: Pelvic organ prolapse (POP) If no, proceed to Section C: Diagnosis
When examining a patient to rule out a pelvic mass or other pathology, complete the following examination and assessment to determine if prolapse is present. If there is no suspicion of prolapse following the examination, continue to Section C: Diagnosis.
Physical examination SECTION A: Screening (Continued)
The following screening tools will help further confirm the type of UI that your patient has and identify if there are any other underlying conditions that need to be treated as well.
Screening tools Urine culture/urine analysis
Perform urinalysis as a part of the initial assessment of a patient with suspected UI. 16  Treat confirmed UTIs with antibiotics 6  Have patient return after UTI has been treated for further assessment 16
Assessing residual urine  Assess residual urine for patients who:
• had bladder surgery • have prolapse • have a neurological condition (multiple sclerosis, strokes, spine/nerve surgeries, diabetic patients with peripheral neuropathy) • have symptoms of incomplete emptying of bladder • have symptoms of frequency and urgency  Measure post-void residual volume 6 by catheterisation or ultrasound 16 /bladder scan 6 If examination of the perineum and assessment of pelvic floor muscles leads to suspected POP, treat POP concurrently with UI and proceed with the following steps. 3
SECTION B: Pelvic organ prolapse
Pelvic organ prolapse (POP) is the herniation of the pelvic organs to or beyond the vaginal walls. Many women with POP experience symptoms that impact daily activities, sexual function, and exercise. 14 The degree of POP doesn't always co-relate with the degree of UI symptoms that a patient experiences.
Screening for POP
Sections:
A Proceed to Section C: Diagnosis to treat UI symptoms concurrently with POP.
Treatment options
Lifestyle interventions
• Advise patient to incorporate the lifestyle changes in Section D: Conservative management of UI into their daily routine
Pelvic floor training
Appropriate for: All patients if they can tolerate vaginal examinations 3,7
How to: Consider referring patient to a pelvic floor physiotherapist/physiotherapist for supervised pelvic floor muscle training for at least 16 weeks as a first option for women with symptomatic POP-Q stage 1 or stage 2 pelvic organ prolapse. If the program is beneficial, advise women to continue pelvic floor muscle training afterwards 6 Consider referring patients to Patient resources section for additional pelvic floor training support
Pessaries
Appropriate for: Patients with symptomatic pelvic organ prolapse How to: Obtain a pessary fitting kit. 3 As wait times for pessary fitting and care may vary, providers can learn to do this either by themselves by referring to the Canadian Family Physician article on pessary fittings 48 or by shadowing an expert in this area. 3
• If the patient has vaginal odour, bleeding, or is post-menopausal, consider a low-dose of topical estrogen in conjunction with pessary use after clinical examination 50, 51 • Refer patients with vaginal erosion and ongoing bleeding to a specialist 3
• Instruct the patient on pessary insertion/removal and care (cleaning and examination), as needed. Also ask about comfort and side effects. 34 Follow-up: Every 6 months with a gynaecological examination included If a patient has symptoms of prolapse, not explained by a physical examination, consider repeating the examination at another scheduled appointment or with the woman in a standing or squatting position. 6 If patient with POP presents with any of the following symptoms, refer them to the appropriate specialist (gastroenterologist, gynaecologist or urologist): 6, 7 • pain • symptoms of obstructed defaecation or faecal incontinence • symptoms not explained by examination findings
• After conducting the examination to detect signs of POP, use the Pelvic Organ Prolapse Quantitation (POP-Q) system 15 to confirm signs of prolapse 13 • POP-Q is an objective, site-specific system for describing and staging POP in women 13
Examination
Sections:
QUID
After taking patient's medical history and conducting a physical examination, use a UI symptom questionnaire to assess and diagnose your patient 9 :
• The Questionnaire for Female Urinary Incontinence Diagnosis (QUID) is a validated tool that has the potential to identify the different types of UI in women. 16 Please use the QUID below to diagnose the type of UI your patient has and proceed to the sections in the tool accordingly. 
Stress urinary incontinence (SUI)
Positive scores to questions 1, 2, 3 implies stress UI • stress score is the total score for questions 1, 2, 3 • > 4 is clinically significant 7,21 • Section D: Conservative management of UI • Section F: Surgical management of UI
Mixed urinary incontinence (MUI)
Mixed UI includes both urge and stress scores 7 Treat the most bothersome symptom first in patients with MUI. 16 • Section D: Conservative management of UI • Section E: Pharmacological management of UI • Section F: Surgical management of UI
Overactive bladder (OAB)
Positive scores to questions 4, 5, 6 implies urge UI or overactive bladder (OAB), urge score = total for questions 4, 5, 6 • > 6 is clinically significant 7, 21 • Section D: Conservative management of UI • Section E: Pharmacological management of UI • Section F: Surgical management of UI
SECTION C: Diagnosis
SECTION D: Conservative management of UI
If the patient has minor UI or presents concerns of UI symptoms, the first-line treatments are conservative therapies. These treatments usually carry the least risk of harm. 16 Advise your patient to incorporate the following into their daily lifestyle routine:
Lifestyle interventions
 Recommend a trial of caffeine reduction to women with overactive bladder 6  Recommend eating more fiber (this can also prevent constipation which can be a cause of UI) 8  Provide smoking cessation strategies to patients who smoke 16  Review type and amount of fluid intake in patients with UI 16  Advise a light reduction in the amount of liquid that the patient drinks 4  Advise patient to cut back on alcohol consumption 3  Advise patients who have a BMI greater than 30 kg/m 2 to lose weight 6 "Have you considered cutting down on any foods or drinks that make your symptoms worse?" 4 "When taking diuretics, aka "water pills", make sure to take them when you will be near a bathroom for a few hours. This medicine can increase your need to urinate." 4 Patients with diabetes "Keep your blood sugars as close to normal as possible, this may help some of your symptoms" 4
Talking Points
Sections:
A B C D E F G Resources References
All patients are eligible for pelvic floor therapy if they can tolerate vaginal examinations. 3, 7 Consider referring your patient to a pelvic floor physiotherapist/physiotherapist for supervised pelvic floor muscle training. 6
Physical therapies
Absorbent containment products, urinals and toileting aids
Only offer absorbent containment products, hand-held urinals or toileting aids to treat UI after other treatments have been tried: 6 • as a coping strategy pending definitive treatment • as an adjunct to ongoing therapy • as long-term management options only after exploring other treatments • Conduct a review (at least once a year) for women who use absorbent containment products for the long-term management of UI 
Considerations before prescribing pharmacological treatment
Pharmacological options
• For anticholinergic medication, side effects can include dry mouth, constipation as well as a reduction of incontinence. 7 • The adverse effects of blurred vision and cognitive impairment indicate that the medication is to be discontinued. Reassess for a new medication to try. 7
• Offer intravaginal estrogens to treat overactive bladder symptoms in postmenopausal women with vaginal atrophy 6 • Offer antimuscarinic (anticholinergic) medicine to treat overactive bladder or mixed urinary incontinence in women 6 • Immediate release (IR) formulation of oxybutynin is the archetype medication in the treatment of OAB 16 • If the first medicine for OAB or MUI is not effective or welltolerated, offer another medicine 6 while considering cost and Ontario Drug Benefit (ODB) coverage • Mirabegron, a beta-3 adrenoceptor agonist, is recommended as an option for treating the symptoms of overactive bladder only for people who have unacceptable side effects or for whom anticholinergic drugs are contraindicated or clinically ineffective 27 • To ensure that medications do not contraindicate with other medicines that your patient is taking, consider consulting each product monograph or a pharmacist
• Do not start medication if there is clinical evidence of acute angle glaucoma or cognitive impairments 7 • Exercise caution with older patients especially those who are at risk of, or have, cognitive dysfunction 16
What not to do:
• Do not offer women flavoxate, propantheline or imipramine to treat urinary incontinence or overactive bladder 6 • Do not use duloxetine as a first-line treatment for women with predominant stress urinary incontinence. Do not routinely offer duloxetine as a second-line treatment for women with stress urinary incontinence, although it may be offered as second-line therapy if women prefer pharmacological to surgical treatment or are not suitable for surgical treatment. If duloxetine is prescribed, counsel women about its adverse effects 6 • Do not offer systemic hormone replacement therapy to treat urinary incontinence 6 "You may not see a lot of benefits until you've been taking the medicine for at least 4 weeks and your symptoms may continue to improve over time" 6
Talking Points
Sections:
A 
SECTION F: Surgical management of UI
For women with overactive bladder that have not responded to non-surgical management or pharmacological treatment and who wish to discuss further treatment options 6 refer patient to a specialist with an interest in incontinence (i.e. gynaecologist or urologist). 3, 7 Discuss the benefits and risks of surgical treatment options for stress urinary incontinence. 6 Refer the patient to a specialist with an interest in incontinence (i.e. gynaecologist or urologist) to discuss all surgical options. 3,7 SECTION G: Follow-up and maintenance
• Offer a face-to-face, telephone or virtual review 4 weeks after starting a new medication. Ask the patient if they are satisfied with the treatment, and: 6 • if the improvement is optimal, continue treatment • if there is no or suboptimal improvement, or intolerable adverse effects, then increase the dose or try an alternative medication, and review again 4 weeks later • Review before 4 weeks if the adverse events of a medication are intolerable • Refer women who have tried taking medication, but for whom it has not been successful or tolerated, to secondary care to consider further treatment 6 • If a medication stops working after an initial successful 4-week review • Offer a review in primary care to women who remain on long-term medication every 12 months, or every 6 months if they are aged over 75
• Follow-up with patients depending on the severity of their condition (e.g. at 3 months, 6 months or at a year) after starting conservative treatment options
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